Amendments to the Specification:

Please replace the paragraph on page 1, line 4, with the following rewritten paragraph:

--This application is a divisional of United States application no. 09/822,823 (now allowed), which is a continuation-in-part of United States application no. 09/579,463 filed May 26, 2000 (now Patent No. 6,448,075) which claims benefit from United States provisional application serial no. 60/203,477 filed on May 11, 2000 (now abandoned); United States provisional application serial no. 60/193,371 filed on March 31, 2000 (now abandoned); and United States provisional application no. 60/136,770 filed on May 28, 1999 (now abandoned), all of which are incorporated herein by reference in their entirety.--

Please replace the paragraph on page 11, line 4 with the following rewritten paragraph:

--Within the context of the present invention, antibodies are understood to include monoclonal antibodies and polyclonal antibodies, antibody fragments (e.g., Fab, and F(ab')2), chimeric antibodies, bifunctional or bispecific antibodies and tetrameric antibody complexes. Antibodies are understood to be reactive against a selected antigen on the surface of a nucleated cell or erythrocyte if they bind with an appropriate affinity (association constant), e.g. greater than or equal to ~~107 M-1~~ 10^7 M^{-1}.--

Please replace the paragraph on page 16, line 1 with the following rewritten paragraph:

--The antibody compositions are made by combining various tetrameric antibody complexes depending on which cells one wishes to deplete. The concentration of the various tetrameric antibody complexes varies: typically antibodies to antigens expressed on nucleated cells are at 10-30~~mg~~ μg/mL in tetrameric complexes. The composition is then diluted 1/10 into the cells so the final concentrations of each anti nucleated cell antibody in the cell suspensions is 1.0-3.0 ~~mg~~ μg/mL.--

Please replace the paragraph on page 16, line 12 with the following rewritten paragraph:

--1. Add 100~~mL~~ μL antibody composition per mL of whole peripheral blood.--

Please replace the paragraph on page 18, line 5 with the following rewritten paragraph:

--4. Count cells and resuspend at 1x~~108~~ 10^8/mL.--

Please replace the paragraph on page 18, line 9 with the following rewritten paragraph:

--8. Add a tetrameric antibody complex specific to a given antigen at a final concentration of 1.0 ~~mg~~ μg/mL, the synthesis of which is described in Example 1.--

Please replace the paragraph on page 20, line 29 with the following rewritten paragraph:

--This example demonstrates the enrichment of breast cancer cells from whole peripheral blood using the method described in Example 2. Cells from the CAMA breast cancer cell line were seeded into samples of whole peripheral blood at a frequency of 1/~~103~~ 10^3, 1/~~104~~ 10^4 and 1/~~105~~ 10^5. Four tumor cell enrichment cocktails of tetrameric antibody complexes were prepared. The antibody composition of the cocktails is listed in Table 11. The results, shown in Table 12, demonstrate that the method of the invention results in greater than 2 log enrichment of tumor cells with 20-50% recovery of tumor cells. The more extensive cocktail offers a greater degree of tumor cell enrichment.--

Please replace the last two rows of Table 1 on page 26 with the following:

TCR~~ab~~ αβ	WT31	BD Biosciences, San Jose, CA
TCR ~~gd~~ γδ	Immu510	IMMUNOTECH, Marseille, France

Please replace lines 20-22 of Table 2 on page 27 with the following:

--~~gd~~ γδ T Cell Enrichment

Anti-

~~ab~~ αβTCR--

Please replace lines 3-5 of Table 2 (Cont'd) on page 28 with the following:

--~~ab~~ αβ T Cell Enrichment

Anti-

~~gd~~ γδ TCR--

Please replace lines 21-23 of Table 2 (Cont'd) on page 29 with the following:

--CD4+ ~~ab~~ αβT Cell Enrichment

Anti-

~~gd~~ γδTCR--

Please replace lines 2-4 of Table 2 (Cont'd) on page 32 with the following:

--CD8+ ~~ab~~ αβT Cell Enrichment

Anti-

~~gd~~ γδTCR--